Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5279411
Max Phase: Preclinical
Molecular Formula: C49H54F4N8O6S2
Molecular Weight: 991.15
Associated Items:
ID: ALA5279411
Max Phase: Preclinical
Molecular Formula: C49H54F4N8O6S2
Molecular Weight: 991.15
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCNC(=O)c2ccc(N3C(=S)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)C3(C)C)cc2F)C(C)(C)C)cc1
Standard InChI: InChI=1S/C49H54F4N8O6S2/c1-28-40(69-27-57-28)30-14-12-29(13-15-30)25-56-43(65)38-23-34(62)26-59(38)44(66)41(47(2,3)4)58-39(63)11-9-7-8-10-20-55-42(64)35-19-18-33(22-37(35)50)61-46(68)60(45(67)48(61,5)6)32-17-16-31(24-54)36(21-32)49(51,52)53/h12-19,21-22,27,34,38,41,62H,7-11,20,23,25-26H2,1-6H3,(H,55,64)(H,56,65)(H,58,63)/t34-,38+,41-/m1/s1
Standard InChI Key: QPHYYAFAFYEWMM-RHMQSKSJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 991.15 | Molecular Weight (Monoisotopic): 990.3544 | AlogP: 7.55 | #Rotatable Bonds: 16 |
Polar Surface Area: 188.07 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 14 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.45 | CX Basic pKa: 2.65 | CX LogP: 6.39 | CX LogD: 6.39 |
Aromatic Rings: 4 | Heavy Atoms: 69 | QED Weighted: 0.05 | Np Likeness Score: -0.92 |
1. Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S.. (2019) Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer., 62 (2): [PMID:30629437] [10.1021/acs.jmedchem.8b01631] |
Source(1):